April, 2024
April 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Erman Akkus: ESMO-2023, hepatobiliary and pancreatic cancers
Mar 27, 2024, 13:02

Erman Akkus: ESMO-2023, hepatobiliary and pancreatic cancers

Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:

“ESMO-2023, hepatobiliary and pancreatic cancers ESMO – Eur. Oncology, EORTC

-Biliary tract cancers
Outcomes worse in extraheoatic CCA than intrahepatic with cis-gem.
tinengotinib as a FGFR2 inhibitor after progression with another FGFR inhibitor.
DESTINY-PanTumor02 trial, trastuzumab deruxtecan in second line for HER-2 positive BTC.

-HCC
AdvanTIG-206 trial, Adding ociperlimab (anti-TIGIT) to tislelizumab (anti-PD1) plus BAT1706 (anti-VEGF) > negative study.

-Pancreatic cancer
GENERATE trial, gemcitabine nab-paclitaxel vs mFOLFIRINOX or S-IROX > favoring gem-nabpacli in Asian population.
PREOPANC-2 trial, neoadjuvant FOLFIRINOX vs Gemcitabine-radiotheraphy in borderline resectable and resectable cancers > no differences.”

Visit the article website.
Source: Erman Akkus/X